Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Second Opinions for Melanocytic Lesions Examined

Dermatol Surg; ePub 2017 Aug 29; Geller, et al

The use of second opinions in clinical practice is greater than that required by laboratory policies, especially for melanocytic tumors of uncertain malignant potential and atypical Spitzoid lesions, a recent study found. Cross-sectional data were collected from 207 pathologists in 10 US states who diagnose melanocytic lesions. A web-based survey ascertained pathologists' professional information, laboratory second opinion policy, use of second opinions, and perceptions of second opinion value for melanocytic lesions. Researchers found:

  • Laboratory policies required second opinions for 31% of pathologists and most commonly required them for melanoma in situ (26%) and invasive melanoma (30%).
  • In practice, most pathologists reported requesting second opinions for melanocytic tumors of uncertain malignant potential (85%) and atypical Spitzoid lesions (88%).
  • Most pathologists perceived that second opinions increased interpretive accuracy (78%) and protected them from malpractice lawsuits (62%).

Citation:

Geller BM, Frederick PD, Knezevich SR. Pathologists' use of second opinions in interpretation of melanocytic cutaneous lesions: Policies, practices, and perceptions. [Published online ahead of print August 29, 2017]. Dermatol Surg. doi:10.1097/DSS.0000000000001256.

This Week's Must Reads

Opioids and the Dermatology Medicare Population, JAMA Dermatology; ePub 2018 Feb 7; Cao, et al

Significant Care Costs Associated with Cellulitis, J Am Acad Dermatol; ePub 2018 Feb 7; St. John, et al

An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al

Underlying Disease Impact on Pyoderma Gangrenosum, J Am Acad Dermatol; ePub 2018 Feb 10; Kaffenberger, et al

FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8

Must Reads in Melanoma

An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al

Melanoma Risk Assessed in Melanoma-Prone Families, J Invest Dermatol; ePub 2018 Feb 2; Tucker, Elder, et al

Validity of Transplant Network Cancer Reporting , J Am Acad Dermatol; 2018 Feb; Garrett, et al

2-mm Biopsy Margin May Decrease Patient Morbidity, J Am Acad Dermatol; 2017 Dec; Terushkin, Ng, et al

Inverted Type-A Melanocytic Nevi Examined, J Cutan Pathol; ePub 2018 Jan 17; Dadras, et al